Compagnie Chargeurs Invest (CRI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
5 Nov, 2026Executive summary
Q3 2026 revenue was €99.4m, up 6.5% reported and 1.6% like-for-like YoY, marking a return to growth across all businesses.
The growth acceleration is expected to continue in H2 2026 and H1 2027, supported by major Museum Studio projects moving into construction and installation.
Financial highlights
9M 2026 revenue was €288.1m, down 8.0% reported and 7.8% like-for-like YoY, reflecting Museum Studio project phasing in H1.
Q3 reported growth included a positive 0.9% currency effect and 4.0% scope effect from Chaplin's World and Harwanne Capital Management acquisitions.
Outlook and guidance
Nearly €300m Museum Studio order book at 30 September 2026 provides visibility over coming quarters; major projects entering build and installation phases support the expected acceleration.
NAV ambition exceeds €1bn by 2031, compared with €556m at 30 June 2026.
Latest events from Compagnie Chargeurs Invest
- Strong cash generation and record order books set up growth after a 2021 rebound.CRI
Q4 2021 - Revenue grew 8.7% like-for-like excluding healthcare as Luxury momentum strengthened.CRI
Q4 2022 - Transformation to high-luxury focus, Novacel sale, and €14/share buyback drive strong outlook.CRI
Q2 2026 - Q1 2026 revenue fell, but strategic transformation accelerates with Novacel divestment and strong order books.CRI
Q1 2026 - Novacel sale and strategic refocus boost financial flexibility and target €1bn NAV by 2030.CRI
Q4 2025 - Stable H1 2025 revenue and NAV growth, strong Museum Studio gains, Novacel disposal under review.CRI
Q2 2025 - Revenue up 11.1% and recurring operating profit up 33.9%, with strong cash flow and reduced net debt.CRI
Q2 2024 - Strong growth, strategic transformation, and all resolutions passed amid market and regulatory risks.CRI
AGM 2025 - Museum Studio and Personal Goods drove 5.6% revenue growth in Q1 2025 amid global challenges.CRI
Q1 2025